Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
Phase 1 Completed
18 enrolled
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
Phase 1 Completed
7 enrolled
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Phase 1 Completed
16 enrolled 16 charts
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Phase 1 Completed
10 enrolled
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
Phase 1 Completed
35 enrolled
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
Phase 1 Completed
11 enrolled
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
Phase 1 Completed
27 enrolled
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase 1 Completed
25 enrolled
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
Phase 1 Completed
40 enrolled
Doxil, Bevacizumab and Temsirolimus Trial
Phase 1 Completed
200 enrolled
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
Phase 1 Completed
63 enrolled 26 charts
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
Phase 1 Completed
12 enrolled
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 1 Completed
74 enrolled
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
Phase 1 Completed
9 enrolled
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
Phase 1 Completed
193 enrolled
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Phase 1 Completed
23 enrolled
Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
Phase 1 Completed
26 enrolled
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
19 enrolled
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
Phase 1 Completed
180 enrolled
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
Phase 1 Completed
23 enrolled
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 1 Completed
3 enrolled
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Phase 1 Completed
72 enrolled
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
Phase 1 Completed
11 enrolled
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Completed
21 enrolled
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Phase 1 Completed
13 enrolled
Erlotinib and Temsirolimus for Solid Tumors
Phase 1 Completed
46 enrolled
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
40 enrolled
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
38 enrolled
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
18 enrolled
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
Phase 1 Completed
39 enrolled
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
Phase 1 Completed
69 enrolled
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Phase 1 Completed
72 enrolled
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
Phase 1 Completed
47 enrolled
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
Phase 1 Completed
25 enrolled
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
Phase 1 Completed
15 enrolled
I-NET
Phase 1 Completed
18 enrolled
Temsirolimus and Radiation for Non-Small Cell Lung Cancer
Phase 1 Completed
10 enrolled
Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Phase 1 Completed
CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
42 enrolled
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
Phase 1 Completed
28 enrolled
Study of Temsirolimus, Topotecan, and Bortezomib
Phase 1 Completed
80 enrolled
Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function
Phase 1 Completed
130 enrolled
CCI-779 in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
15 enrolled
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
Phase 1 Completed
28 enrolled